Clinical Trials Logo

CDKL5 Deficiency Disorder clinical trials

View clinical trials related to CDKL5 Deficiency Disorder.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05249556 Not yet recruiting - Clinical trials for CDKL5 Deficiency Disorder

Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old

Start date: July 2024
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy, safety, and tolerability of ganaxolone (GNX) compared with placebo (PBO) as adjunctive therapy to the participant's standard anti-epileptic medication for the treatment of seizures in pediatric patients from 6 months to less than 2 years old with genetically confirmed CDD during a 12-week, DB phase. Pharmacokinetic (PK) assessments and population PK analyses will also be performed during this time. The DB phase will be followed by an optional long-term OL phase at which time all participants will receive GNX as an adjunct to their standard anti-seizure medication. Efficacy, safety and tolerability, and PK assessments will continue to be performed.